Greetings!

First, we want to wish you happy holidays, a merry festive season and a great start into 2023.
The past year has been full of things that moved us. Many interesting developments and exciting partnerships pushed us forward as a company. We would like to take the opportunity to look back at these in the following newsletter.
The thing that moved us most last year, was meeting you all once again at several events after such a long time. So thank you all for stopping by, it was great to see you and we hope to meet again very soon.

Your EZ Medical Team!
Looking Back at 2022
All four Eckert & Ziegler Medical business units were working effortlessly to advance our cause of improving nuclear medicine and radiation therapy all over the globe.
In this journey, there were some exciting milestones. In the following, we would like to revisit some of these.
The Return of the Congress

Returning to face-to-face events was a major shift in 2022. After two years of virtual congresses and online workshops, we were finally able to tour the world's expo centers again and to meet you all in person.
We were involved in over 40 events, big and small, and have to admit: We missed it.
So we will be out there again next year and hope to see even more of your faces around.

To have a preview of a handful of meetings we will definitely participate in next year, just visit our event page.
Radiopharma
Joint Venture with Atom Mines LLC for Ytterbium-176 supply

In January, we kicked off the year by entering into a joint venture with Austin, TX based Atom Mines, LLC, a producer of Ytterbium-176 and subsidiary of the Pointsman Foundation.
The agreement also gives us exclusive long-term access to this precursor for Lutetium-177, which is produced through an innovative process partially funded by us and developed by Atom Mines.
Cooperation with UJF to produce Actinium-225

In May, we entered into a long-term collaboration agreement with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, UJF).
We will provide UJF with several million euros for investments in hot cells and equipment as well as Radium-226 as a starting material for their experimental work.
In return, we will gain exclusive access to their pilot unit and joint rights to the process steps developed for large-scale, commercial Ac-225 production
Becoming the CMO for Ratio's Lu-177 and Ac-225 candidates

This year also marked the successful launch of our GMP suites.
The first project to be realized in our Boston suite is the joint development and manufacture of innovative radiopharmaceutical products based on Lutetium-177 and Actinium-225 with Ratio Therapeutics Inc.

The agreement covers the development of a validated manufacturing process and the GMP-compliant production of clinical investigational products.
Provision of Radionuclides

We are steadily working on expanding our portfolio of radionuclides and offering our existing portfolio in higher qualities and bigger quantity.

In 2022, this was already bearing fruits, as we could gain the first large-scale customers for our Lutetium-177 and Actinium-225.

Click the buttons below to find out more about the corresponding agreements.
Lab Devices
Development Projects

In our Lab Devices unit, we have started a number of interesting development projects. One of these is an exciting collaboration with Precirix to develop a reliable and efficient automated production process for their 68Ga-based diagnostic tools.
Furthering our Alpha Competence

Another focus is to prepare our customers for the future of nuclear medicine and the "alpha wave" that is sure to come. For this reason, we are developing reliable production methods for alpha compounds on our Modular-Lab eazy and have established quality control routines for alpha emitters on our AR-2000 and MiniScanPRO TLC scanners.
Engineering
Exciting Projects on the Horizon

Our Dresden-based hot cell experts were very busy this year. They realized customized work environments for numerous customers and our own sites in Berlin and Wilmington.
Furthermore, they received orders for challenging new projects such as building the production line for Northstar Medical Radioisotopes' Actinium-225 production.
Radiation Therapy
Back to the Roots

After the divestment of our HDR business in 2021, we further narrowed our focus by divesting our X-ray therapy business this year. This allowed us to concentrate on our core business of LDR prostate and ophthalmic brachytherapy.
To assist ophthalmologists with the latter, we produced a video detailing the procedure of treating a choroidal melanoma with Ru-106 plaque therapy.
The beauty of traditions is that we repeat them
This time of year more so then others is about giving. As every year it is a matter close to our hearts to support the Björn-Schulz-Foundation here in Berlin, Germany, with a donation instead of spending the money to send out cards and gifts to our associates.

This foundation dedicated itself to accompanying terminally ill children, adolescents and their families. Their work is only possible due to donations and the work of volunteers. As we wholeheartedly support the foundation's mission, we are confident that you agree with our choice. 

In case that you would like to support this cause as well, you can make a donation to the following account:

Recipient: Björn Schulz Stiftung
IBAN: DE 34 1002 0500 0001 1456 00
BIC: BFSWDE33XXX
Please contact us to find out more about our products and services, tell us about an application you have, or request a quotation. Please send your queries to medical@ezag.com or call us +49 30-941084-252.
 
Sincerely,  
Your Sales & Marketing Team from
Eckert & Ziegler Medical
STAY CONNECTED